{"id":"NCT01797081","sponsor":"Allergan","briefTitle":"BOTOX速 in the Treatment of Crow's Feet Lines in Japan","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-31","primaryCompletion":"2013-07-18","completion":"2014-07-07","firstPosted":"2013-02-22","resultsPosted":"2015-02-10","lastUpdate":"2019-04-16"},"enrollment":300,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Lateral Canthus Rhytides","Crow's Feet Lines"],"interventions":[{"type":"BIOLOGICAL","name":"botulinum toxin Type A (24 U)","otherNames":["BOTOX速"]},{"type":"BIOLOGICAL","name":"botulinum toxin Type A (12 U)","otherNames":["BOTOX速"]},{"type":"OTHER","name":"Normal Saline","otherNames":[]}],"arms":[{"label":"Botulinum toxin Type A (24U)","type":"EXPERIMENTAL"},{"label":"Botulinum toxin Type A (12U)","type":"EXPERIMENTAL"},{"label":"Placebo/Botulinum toxin Type A (24U)","type":"OTHER"},{"label":"Placebo/Botulinum toxin Type A (12U)","type":"OTHER"}],"summary":"This study will evaluate the safety and efficacy of BOTOX速 (botulinum toxin Type A) compared to placebo for the treatment of Crow's Feet Lines (Lateral Canthus Rhytides).","primaryOutcome":{"measure":"Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle Scale-Asian (FWS-A)","timeFrame":"Day 30","effectByArm":[{"arm":"Botulinum Toxin Type A (24U)","deltaMin":68.3,"sd":null},{"arm":"Botulinum Toxin Type A (12U)","deltaMin":56.6,"sd":null},{"arm":"Placebo","deltaMin":8.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":6},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["28733805"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":151},"commonTop":["Nasopharyngitis"]}}